Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation
Abstract
Aim: To compare the satisfaction of patients treated with vitamin K antagonists (VKA) with that of patients treated with direct oral anticoagulants (DOACs) and to determine the impact on quality of life of both treatments in patients with nonvalvular atrial fibrillation (NVAF). Methods: Cross-sectional multicenter study in which outpatients with NVAF completed the ACTS (Anti-Clot Treatment Scale), SAT-Q (Satisfaction Questionnaire) and EQ-5D-3L (EuroQol 5 dimensions questionnaire, 3 level version) questionnaires. Results: The study population comprised 1337 patients, of whom 587 were taking DOACs and 750 VKAs. Compared with VKAs, DOACs were more commonly prescribed in patients with a history of stroke and in patients with a higher thromboembolic risk. The study scores were as follows: SAT-Q: 63.8 ± 17.8; EQ-5D-3L total score: 75.6 ± 20.9; visual analog scale: 63.1 ± 20.6; ACTS Burdens: 51.8 ± 8.4 and ACTS Benefits: 11.9 ± 2.4. The ACTS Burdens score and ACTS Benefits score were higher with DOACs than with VKAs (54.83 ± 6.11 vs 49.50 ± 9.15; p < 0.001 and 12.36 ± 2.34 vs 11.48 ± 2.46; p < 0.001 respectively). Conclusion: NVAF patients treated with oral anticoagulants had many comorbidities and a high thromboembolic risk. Satisfaction and quality of life with oral anticoagulants were high, although they were both better with DOACs than with VKAs.
Supplementary Material
File (suppl_data.zip)
- Download
- 52.44 KB
References
1.
Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat. Rev. Cardiol. 11, 639–654 (2014).
2.
Barrios V, Calderon A, Escobar C, De la Figuera M. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev. Esp. Cardiol. (Engl. Ed.) 65, 47–53 (2012).
3.
Camm AJ, Lip GYH, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 33, 2719–2747 (2012).
4.
Masjuán J, Álvarez-Sabín J, Blanco M et al. [Current management of antithrombotic treatment in patients with non valvular atrial fibrillation and prior history of stroke or transient ischemic attack]. Rev. Neurol. 59, 25–36 (2014).
5.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857–867 (2007).
6.
Barrios V, Escobar C. Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert Rev. Cardiovasc. Ther. 11, 129–141 (2013).
7.
Ynsaurriaga FA, Peinado RP, Ormaetxe Merodio JM. Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation. Future Cardiol. 10, 381–393 (2014).
8.
Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383, 955–962 (2014).
9.
Suárez C, Pose A, Montero-Pérez-Barquero M et al. [Validation of satisfaction questionnaire ACTS in outpatients with atrial fibrillation treated with oral anticoagulants attended in Spain. ALADIN study]. Med. Clin. (Barc). 147, 192–198 (2016).
10.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373–383 (1987).
11.
SEMI, semFYC, FAECAP. Care process of patients with complex chronic diseases and pluripathology. www.fesemi.org/documentos/1385470163/publicaciones/guias/proceso-asistencial-enfermedades-cronicas-complejas.pdf.
12.
Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. 69, 236–239 (1993).
13.
Cano SJ, Lamping DL, Bamber L, Smith S. The anti-clot treatment scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual. Life Outcomes 10, 120 (2012).
14.
Protheroe J, Fahey T, Montgomery AA, Peters TJ. Effects of patients’ preferences on the treatment of atrial fibrillation: observational study of patient-based decision analysis. West. J. Med. 174, 311–315 (2001).
15.
Man-Son-Hing M, Gage BF, Montgomery AA et al. Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. Med. Decis. Making 25, 548–559 (2005).
16.
Barrios V, Escobar C, Prieto L et al. Anticoagulation control in patients with nonvalvular atrial fibrillation attended at primary care centers in spain: the PAULA study. Rev. Esp. Cardiol. (Engl. Ed.) 68, 769–776 (2015).
17.
Lip GY, Rushton-Smith SK, Goldhaber SZ et al. GARFIELD-AF Investigators. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes 8(2 Suppl. 1), S12–S20 (2015).
18.
Bertomeu-González V, Anguita M, Moreno-Arribas J et al. Quality of anticoagulation with vitamin K antagonists. Clin. Cardiol. 38, 357–364 (2015).
19.
Razouki Z, Ozonoff A, Zhao S, Rose AJ. Pathways to poor anticoagulation control. J. Thromb. Haemost. 12, 628–634 (2014).
20.
Costa GL, Lamego RM, Colosimo EA, Valacio RA, Moreira Mda C. Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study. Clin. Ther. 34, 1511–1520 (2012).
21.
Hasan SS, Teh KM, Ahmed SI, Chong DW, Ong HC, Naina B. Quality of life (QoL) and International Normalized Ratio (INR) control of patients attending anticoagulation clinics. Public Health 129, 954–962 (2015).
22.
Wang Y, Kong MC, Lee LH, Ng HJ, Ko Y. Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb. Res. 133, 550–554 (2014).
23.
Camm AJ, Amarenco P, Haas S et al; XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur. Heart J. 37, 1145–1153 (2016).
24.
Beyer-Westendorf J, Förster K, Pannach S et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden DOAC registry. Blood 124, 955–962 (2014).
25.
Beyer-Westendorf J, Ebertz F, Förster K et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden DOAC Registry. Thromb. Haemost. 113, 1247–1257 (2015).
26.
Álvarez-Otero J, de la Fuente-Aguado J, Arias-Castaño JC, González-González L, Puerta-Louro R, Araújo-Fernández S. [Dabigatran: experience in standard clinical practice]. Rev. Clin. Esp. 215, 385–390 (2015).
27.
Beyer-Westendorf J, Werth S, Tittl L, Michalski F, Marten S, Weiss N. Real life efficacy and safety of apixaban for stroke prevention in atrial fibrillation – results of the prospective DOAC registry (NCT01588119). Presented at: The XXV Congress of the International Society on Thrombosis and Haemostasis. Toronto, Canada, 20–25 June 2015 (Abstract: AS098).
28.
Marvig CL, Verhoef TI, de Boer A et al. Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. Thromb. Res. 136, 69–75 (2015).
29.
Corbi IS, Dantas RA, Pelegrino FM, Carvalho AR. Health related quality of life of patients undergoing oral anticoagulation therapy. Rev. Lat. Am. Enfermagem. 19, 865–873 (2011).
30.
Turker Y, Ekinozu I, Aytekin S et al. Comparison of changes in anxiety and depression level between dabigatran and warfarin use in patients with atrial fibrillation. Clin. Appl. Thromb. Hemost. 23(2), 164–167 (2017).
31.
Fareau S, Baumstarck K, Farcet A, Molines C, Auquier P, Retornaz F. [Quality of life of elderly people on oral anticoagulant for atrial fibrillation: VKA versus direct oral anticoagulants]. Geriatr. Psychol. Neuropsychiatr. Vieil. 13, 45–54 (2015).
32.
Alegret JM, Viñolas X, Arias MA et al. New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation. Int. J. Med. Sci. 11, 680–684 (2014).
33.
Coleman CI, Coleman SM, Vanderpoel J et al. Patient satisfaction with warfarin- and non-warfarin-containing thromboprophylaxis regimens for atrial fibrillation. J. Investig. Med. 61, 878–881 (2013).
34.
Coleman CI, Haas S, Turpie AG et al. Impact of switching from vitamin K antagonist to rivaroxaban on satisfaction with anticoagulation therapy: the XANTUS-ACTS substudy. Clin. Cardiol. 39(10), 565–569 (2016).
35.
Boom MS, Berghuis EM, Nieuwkerk PT, Pinedo S, Büller HR. When do patients prefer a direct oral anticoagulant over a vitamin K antagonist? Neth. J. Med. 73, 368–372 (2015).
36.
Ghijben P, Lancsar E, Zavarsek S. Preferences for oral anticoagulants in atrial fibrillation: a best-best discrete choice experiment. Pharmacoeconomics 32, 1115–1127 (2014).
37.
Soliman Hamad MA, van Eekelen E, van Agt T, van Straten AH. Self-management program improves anticoagulation control and quality of life: a prospective randomized study. Eur. J. Cardiothorac. Surg. 35, 265–269 (2009).
38.
Böttger B, Thate-Waschke IM, Bauersachs R, Kohlmann T, Wilke T. Preferences for anticoagulation therapy in atrial fibrillation: the patients’ view. J. Thromb. Thrombolysis 40, 406–415 (2015).
39.
Laliberté F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv. Ther. 29, 675–690 (2012).
Information & Authors
Information
Published In
Copyright
© Future Medicine Ltd.
History
Published online: 29 March 2017
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation. (2017) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2016-0078
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Manuel C. Olma, Lena Steindorf‐Sabath, Serdar Tütüncü, Claudia Kunze, Cornelia Fiessler, Paulus Kirchhof, Joanna Dietzel, Johannes Schurig, Patrick Oschmann, Ludwig Niehaus, Christian Urbanek, Götz Thomalla, Darius G. Nabavi, Joachim Röther, Ulrich Laufs, Roland Veltkamp, Peter U. Heuschmann, Karl Georg Haeusler, Matthias Endres, The Role of Atrial Fibrillation and Oral Anticoagulation Status in Health‐Related Quality of Life 12 Months After Ischemic Stroke or TIA, Brain and Behavior, 10.1002/brb3.70248, 15, 1, (2025).
- Pilar Cabanas-Grandío, Laila González-Melchor, María Vázquez Caamaño, Emiliano Fernández-Obanza Windcheid, Eva González Babarro, Olga Durán Bobín, Miriam Piñeiro Portela, Oscar Prada Delgado, Juliana Elices Teja, Mario Gutiérrez Feijoo, Evaristo Freire, Oscar Díaz Castro, Javier Muñiz García, Javier García-Seara, Carlos González-Juanatey, Health-Related Quality of Life and Satisfaction in Atrial Fibrillation Patients on Anticoagulant Therapy: Differences between Vitamin K Antagonists and Direct Oral Anticoagulants; Results from the Multicentre REGUEIFA Registry, Journal of Clinical Medicine, 10.3390/jcm13175283, 13, 17, (5283), (2024).
- Vanelise Zortea, Karine Duarte Curvello, Diogo Pilger, Antonios Douros, Lisiane Freitas Leal, Tatiana da Silva Sempé, Tatiane da Silva Dal Pizzol, Adherence and Quality of Life in Non-Valvular Atrial Fibrillation With Direct Oral Anticoagulants Versus Vitamin K Antagonists: A Systematic Review, International Journal of Cardiovascular Sciences, 10.36660/ijcs.20220115, 36, (2023).
- Samah W. Al-Jabi, Amal Abu Dalu, Amer A. Koni, Maher R. Khdour, Adham Abu Taha, Riad Amer, Sa’ed H. Zyoud, The relationship between self-efficacy and treatment satisfaction among patients with anticoagulant therapy: a cross-sectional study from a developing country, Thrombosis Journal, 10.1186/s12959-022-00374-2, 20, 1, (2022).
- Young-Soo Lee, Yong Seog Oh, Eue-Keun Choi, Alan Koay Choon Chern, Panyapat Jiampo, Aurauma Chutinet, Dicky Armein Hanafy, Prabhav Trivedi, Dongmei Zhai, Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study, Open Heart, 10.1136/openhrt-2021-001745, 8, 2, (e001745), (2021).
- Miren Gabilondo, Jesús Loza, Angel Pereda, Ohiane Caballero, Nerea Zamora, Ania Gorostiza, Javier Mar, Quality of life in patients with nonvalvular atrial fibrillation treated with oral anticoagulants, Hematology, 10.1080/16078454.2021.1892329, 26, 1, (277-283), (2021).
- Diana-Leh-Ching Ng, Natasya Marliana Bt Abdul Malik, Chee-Shee Chai, Greta-Miranda-Kim-Choo Goh, Seng-Beng Tan, Ping-Chong Bee, Gin-Gin Gan, Asri B. Said, Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study, Health and Quality of Life Outcomes, 10.1186/s12955-020-01600-z, 18, 1, (2020).
- Ethan Fry, Harini Bollempali, Keith Suarez, Javier Banchs, Jeffrey Michel, Watchman outcomes comparing post-implantation anticoagulation with warfarin versus direct oral anticoagulants, Journal of Interventional Cardiac Electrophysiology, 10.1007/s10840-020-00790-2, 61, 1, (137-144), (2020).
- Olga Gavín Sebastián, Macarena Izuzquiza Fernández, Raquel Martínez Fernández, Luis Palomera Bernal, Use of Rivaroxaban in Patients Attending a Hematology Unit in Clinical Practice, Future Cardiology, 10.2217/fca-2018-0086, 15, 5, (347-353), (2019).
- V. Barrios, C. Escobar, G. Barón Esquivias, J.J. Gómez Doblas, E. Recalde del Vigo, L. Segura Martínez, P. Alvarez Garcia, F. Alonso Valladares, J. Toril Lopez, J.M. Chopo Alcubilla, Quality of life, adherence and satisfaction of patients with auricular fibrillation treated with dabigatran or vitamin K antagonists, Revista Clínica Española (English Edition), 10.1016/j.rceng.2018.12.012, 219, 6, (285-292), (2019).